convalescent plasma treatment for COVID-19: living meta-analysis of clinical studies

Table Graph

convalescent plasma treatment - versus control - for COVID 19 hospitalized pdf xlsx method abbreviations

Outcome	Relative effect 95%CI	Trt. better when	I2	k (RCT/OBS)	Bayesian probability	Overall ROB	Publication bias	Degree of certainty	Endpoint importance	Published MA
efficacy endpoints 00
death D28	0.99 [0.93, 1.05]	< 1	0%	24 studies (27/-)	63.9 %	some concern	critical	moderate	crucial	-
death or transfer to ICU	1.07 [0.73, 1.57]	< 1	0%	1 study (1/-)	36.6 %	NA	not evaluable		crucial	-
deaths	0.98 [0.92, 1.04]	< 1	0%	37 studies (43/-)	77.4 %	some concern	critical	moderate	crucial	1
deaths (time to event analysis only)	0.99 [0.79, 1.24]	< 1	0%	7 studies (7/-)	54.7 %	some concern	not evaluable	moderate	crucial	-
clinical deterioration	0.87 [0.71, 1.06]	< 1	9%	5 studies (6/-)	91.7 %	some concern	not evaluable	moderate	important	-
clinical improvement	1.09 [0.87, 1.38]	> 1	39%	8 studies (8/-)	77.9 %	some concern	not evaluable	moderate	important	-
clinical improvement (14-day)	2.27 [0.90, 5.72]	> 1	0%	1 study (1/-)	95.9 %	NA	not evaluable		important	-
clinical improvement (28-day)	1.33 [0.83, 2.14]	> 1	53%	5 studies (5/-)	88.1 %	some concern	not evaluable	moderate	important	-
clinical improvement (7-day)	0.98 [0.27, 3.58]	> 1	0%	1 study (1/-)	48.8 %	NA	not evaluable		important	-
clinical improvement (time to event analysis only)	1.08 [0.90, 1.29]	> 1	0%	5 studies (5/-)	80.5 %	low	not evaluable	high	important	-
death or ventilation	0.98 [0.94, 1.03]	< 1	0%	5 studies (5/-)	79.2 %	some concern	not evaluable	moderate	important	-
hospital discharge	1.00 [0.94, 1.07]	> 1	0%	3 studies (3/-)	52.3 %	some concern	not evaluable	moderate	important	-
mechanical ventilation	0.83 [0.64, 1.08]	< 1	24%	7 studies (8/-)	91.7 %	some concern	not evaluable	moderate	important	1
mechanical ventilation (time to event analysis only)	0.97 [0.62, 1.52]	< 1	0%	2 studies (2/-)	55.5 %	some concern	not evaluable	moderate	important	-
viral clearance	1.10 [0.19, 6.30]	> 1	0%	2 studies (2/-)	54.1 %	some concern	not evaluable	moderate	important	-
viral clearance by day 14	0.96 [0.77, 1.20]	> 1	0%	2 studies (2/-)	35.7 %	some concern	not evaluable	moderate	important	-
viral clearance by day 7	0.87 [0.65, 1.16]	> 1	0%	2 studies (3/-)	17.4 %	some concern	not evaluable	moderate	important	-
ICU admission	0.67 [0.32, 1.41]	< 1	1%	2 studies (2/-)	85.6 %	some concern	not evaluable	moderate	non important	-
off oxygenation	0.26 [0.02, 2.88]	> 1	0%	1 study (1/-)	13.8 %	NA	not evaluable		non important	-
safety endpoints 00
serious adverse events	1.19 [0.94, 1.50]	< 1	45%	6 studies (6/-)	7.8 %	some concern	not evaluable	moderate	important	-
adverse events	1.08 [0.86, 1.37]	< 1	0%	2 studies (2/-)	24.8 %	some concern	not evaluable	moderate	non important	-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.

convalescent plasma treatment - versus control - for COVID 19 hospitalized pdf xlsx method abbreviations

efficacy endpoints 00

safety endpoints 00